| Literature DB >> 28406644 |
Jordi-Amat Cuello-Garibo1, Elena Pérez-Gallent1, Lennard van der Boon1, Maxime A Siegler2, Sylvestre Bonnet1.
Abstract
Ruthenium polypyridyl complexes are good candidates for photoactivated chemotherapy (PACT) provided that they are stable in the dark but efficiently photosubstitute one of their ligands. Here the use of the natural amino acidEntities:
Year: 2017 PMID: 28406644 PMCID: PMC5415878 DOI: 10.1021/acs.inorgchem.6b02794
Source DB: PubMed Journal: Inorg Chem ISSN: 0020-1669 Impact factor: 5.165
Figure 1Crystal structures of (a) [2b]PF6 and (b) [2b-2H]PF6. Hexafluorophosphate counteranions, lattice H2O, and disorder have been omitted for clarity.
Scheme 1Structures of the Complexes [1a]PF6, [2a]PF6, [2b]PF6, and [3a]PF6
Scheme 2Synthesis of [3a]PF6, [2a]PF6, and [2b]PF6
(a) (i) bpy (0.8 equiv), ethylene glycol, 3.5 h, 190 °C, pressure tube; (ii) KPF6, 79%. (b) MeCN, 25 °C, white-light xenon lamp, 59%. (c) l-prol (2.5 equiv), K2CO3 (1.25 equiv), ethylene glycol, 40 min, 190 °C, pressure tube. (d) (i) l-prol (2.2 equiv), K2CO3 (1.1 equiv), ethylene glycol, 45 min, 190 °C, pressure tube; (ii) KPF6, 56%.
Selected Bond Lengths (Å) and Angles (deg) for [2b]PF6 and [2b-2H]PF6
| [ | [ | |
|---|---|---|
| Ru1–O1 | 2.100(3) | 2.111(1) |
| Ru1–N1 | 2.024(3) | 2.047(1) |
| Ru1–N2 | 2.067(4) | 2.066(2) |
| Ru1–N3 | 2.074(3) | 2.074(2) |
| Ru1–N4 | 2.098(4) | 2.067(2) |
| Ru1–N5 | 2.143(3) | 2.046(1) |
| N5–C26 | 1.510(5) | 1.305(3) |
| C25–C26–N5 | 115.5(2) | 106.0(3) |
| C23–N5–C26–C27 | 122.1(4) | –174.4(2) |
Figure 2Evolution of the UV–vis spectra of a 0.078 mM solution of [1a]PF6 in PBS irradiated at 298 K with a 493 nm LED at 12.0 mW·cm–2 (a) under air and (b) under argon. (c) Evolution of the absorbance at 473 nm upon irradiation under air (dotted line), under air in the presence of 5 mM GSH (dashed line), and under argon (solid line).
Figure 3MS spectrum of a 0.078 mM solution of [1a]PF6 in PBS after light irradiation at 298 K with a 493 nm LED at 12.0 mW·cm–2 (a) under air, (b), under air in the presence of 5 mM GSH, and (c) under argon. The conditions are detailed in Table S2.
Scheme 3Scheme of the Photoisomerization and Photoxidation Observed upon Visible-Light Irradiation of [1a]PF6 in PBS at 298 K with a 493 nm LED at 12.0 mW·cm–2
Figure 4(a) Evolution of the absorption at 500 nm of a solution of [1a]PF6 (0.078 mM, red circles), [2a]PF6 (0.032 mM, green squares), and [3a]PF6 (0.077 mM, black triangles) in PBS upon irradiation under air with a 493 nm LED at 12.0, 8.7, and 11.0 mW·cm–2, respectively. The conditions are detailed in Table S2. (b) Evolution of the 1H NMR of a D2O solution of (b) [2a]PF6 (2.7 mg in 0.7 mL, circles) and (c) [2b]PF6 (2.6 mg in 0.7 mL, triangles) upon light irradiation with the beam of a xenon lamp filtered with a 450 nm blue-light filter under air. The conditions are detailed in the Supporting Information.
Figure 5(a) Evolution of the UV–vis spectra of a solution of (a) [1a]PF6 (0.071 mM), (b) [2a]PF6 (0.092 mM), (c) [2b]PF6 (0.121 mM), and (d) [3a]PF6 (0.07 mM) in MeCN upon irradiation under argon with a 493 nm LED at 8.2, 8.3, 7.8, and 8.3 mW·cm–2. The conditions are detailed in Table S2.